William Blair Reiterates Market Perform Rating on Allakos Inc. (ALLK), lirentelimab May Still Have Path for Approval in EGIDs
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated a Market Perform rating on Allakos Inc. (NASDAQ: ALLK). following results from the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
